186 related articles for article (PubMed ID: 37948046)
21. Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676.
Varnäs K; Juréus A; Johnström P; Ahlgren C; Schött P; Schou M; Gruber S; Jerning E; Malmborg J; Halldin C; Afzelius L; Farde L
J Pharmacol Exp Ther; 2016 Sep; 358(3):464-71. PubMed ID: 27402278
[TBL] [Abstract][Full Text] [Related]
22. Developing a cassette microdosing approach to enhance the throughput of PET imaging agent screening.
Xiao H; Sun M; Zhao R; Hong H; Zhang A; Zhang S; Liu F; Zhang Y; Liu Y; Zhu L; Kung HF; Qiao J
J Pharm Biomed Anal; 2018 May; 154():48-56. PubMed ID: 29533858
[TBL] [Abstract][Full Text] [Related]
23. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
Lappin G; Garner RC
Nat Rev Drug Discov; 2003 Mar; 2(3):233-40. PubMed ID: 12612650
[TBL] [Abstract][Full Text] [Related]
24. Small Molecule PET Tracers in Drug Discovery.
Donnelly DJ
Semin Nucl Med; 2017 Sep; 47(5):454-460. PubMed ID: 28826520
[TBL] [Abstract][Full Text] [Related]
25. Target engagement in lead generation.
Durham TB; Blanco MJ
Bioorg Med Chem Lett; 2015 Mar; 25(5):998-1008. PubMed ID: 25630223
[TBL] [Abstract][Full Text] [Related]
26. PET technology for drug development in psychiatry.
Arakawa R; Takano A; Halldin C
Neuropsychopharmacol Rep; 2020 Jun; 40(2):114-121. PubMed ID: 32463584
[TBL] [Abstract][Full Text] [Related]
27. Nonhuman primate positron emission tomography neuroimaging in drug abuse research.
Howell LL; Murnane KS
J Pharmacol Exp Ther; 2011 May; 337(2):324-34. PubMed ID: 21317354
[TBL] [Abstract][Full Text] [Related]
28. Radiotracer development in psychiatry.
Pimlott SL
Nucl Med Commun; 2005 Mar; 26(3):183-8. PubMed ID: 15722898
[TBL] [Abstract][Full Text] [Related]
29. Radionuclide imaging of liposomal drug delivery.
van der Geest T; Laverman P; Metselaar JM; Storm G; Boerman OC
Expert Opin Drug Deliv; 2016 Sep; 13(9):1231-42. PubMed ID: 27351233
[TBL] [Abstract][Full Text] [Related]
30. Positron emission tomography and drug discovery: contributions to the understanding of pharmacokinetics, mechanism of action and disease state characterization.
Klimas MT
Mol Imaging Biol; 2002 Oct; 4(5):311-37. PubMed ID: 14537107
[TBL] [Abstract][Full Text] [Related]
31. Positron emission tomography: ligand imaging.
Moghbel M; Newberg A; Alavi A
Handb Clin Neurol; 2016; 135():229-240. PubMed ID: 27432668
[TBL] [Abstract][Full Text] [Related]
32. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development.
Halldin C; Gulyás B; Farde L
Curr Pharm Des; 2001 Dec; 7(18):1907-29. PubMed ID: 11772357
[TBL] [Abstract][Full Text] [Related]
33. Using positron emission tomography to facilitate CNS drug development.
Lee CM; Farde L
Trends Pharmacol Sci; 2006 Jun; 27(6):310-6. PubMed ID: 16678917
[TBL] [Abstract][Full Text] [Related]
34. [Molecular imaging in the drug development of psychotropics using positron emission tomography].
Takano H; Takahashi H; Ito H; Suhara T
Brain Nerve; 2007 Mar; 59(3):215-20. PubMed ID: 17370647
[TBL] [Abstract][Full Text] [Related]
35. [Clinical evaluation of CNS drugs with PET].
Takano A
Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Apr; 29(2):61-5. PubMed ID: 19562943
[TBL] [Abstract][Full Text] [Related]
36. Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders.
Lopresti BJ; Royse SK; Mathis CA; Tollefson SA; Narendran R
J Neurochem; 2023 Feb; 164(3):364-400. PubMed ID: 35536762
[TBL] [Abstract][Full Text] [Related]
37. Microdosing studies in humans: the role of positron emission tomography.
Bauer M; Wagner CC; Langer O
Drugs R D; 2008; 9(2):73-81. PubMed ID: 18298126
[TBL] [Abstract][Full Text] [Related]
38. Human Positron Emission Tomography Neuroimaging.
Hooker JM; Carson RE
Annu Rev Biomed Eng; 2019 Jun; 21():551-581. PubMed ID: 31167104
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of drug penetration into the brain: a double study by in vivo imaging with positron emission tomography and using an in vitro model of the human blood-brain barrier.
Josserand V; Pélerin H; de Bruin B; Jego B; Kuhnast B; Hinnen F; Ducongé F; Boisgard R; Beuvon F; Chassoux F; Daumas-Duport C; Ezan E; Dollé F; Mabondzo A; Tavitian B
J Pharmacol Exp Ther; 2006 Jan; 316(1):79-86. PubMed ID: 16210395
[TBL] [Abstract][Full Text] [Related]
40. PET and SPECT imaging of the opioid system: receptors, radioligands and avenues for drug discovery and development.
Lever JR
Curr Pharm Des; 2007; 13(1):33-49. PubMed ID: 17266587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
